Pharma BD Deal Intelligence

Gilead Sciences, Inc. / Tibotec Pharmaceuticals (Janssen)

2011 · Co-Development · Complete

Announcement Sentiment

Strongly positive

Gilead and Tibotec (J&J) finalized a co-development agreement for a single-tablet HIV regimen pairing Prezista with cobicistat, emtricitabine and GS 7340 (later TAF). Financial terms not disclosed; strategically significant HIV combo deal.

Did it work? Outcome assessment

Strategic verdict

Achieved Stated Rationale

Financial impact

Accretive

Pipeline outcome

Assets Advanced

Assessment window: 10yr post-close.

Key facts

Announced Jun 28, 2011
Closed Jun 28, 2011
Deal type Co-Development
Therapeutic area HIV-1 infection
Indications HIV-1 infection
Key assets Fixed-dose combination of Prezista (darunavir), cobicistat, GS 7340 (TAF), Emtriva (emtricitabine)
Mechanism Single-tablet HIV regimen (PI + boosting agent + 2x NRTI)

See the full interactive analysis, sources & comparables →

← Browse all deals · How we score deals